Cooper Consumer Health announces the appointment of Bart Meermans as CEO and the acquisition of Lashilé Beauty

2021 November | PRESS RELEASE

8 November 2021

The acquisition of Cooper Consumer Health by CVC Capital Partners Fund VII (“CVC”) is completed

Cooper Consumer Health (“Cooper”) a leading European independent over-the-counter drug manufacturer and distributor, is pleased to announce the appointment of Bart Meermans as its new Chief Executive Officer and the agreement to acquire French consumer health food supplement business, Lashilé Beauty.

Bart Meermans has a wealth of industry experience having spent the last ten years at Reckitt Benckiser in a number of roles, most recently as Senior Vice President responsible for leading the company’s health businesses in Africa, Middle East, Turkey and Pakistan. Under his leadership the regions completed a significant digital transformation, which tripled online sales. Prior to this, Bart spent fifteen years in managerial roles at Omega Pharma and Procter & Gamble. Bart will succeed Bauke Rouwers, who will step down from his current CEO role, effective immediately.

Cooper has also agreed to acquire French nutraceutical company Lashilé Beauty, the market-leader in the fast-growing gummy dietary supplement category in France. The business fits well the bolt-on strategy of Cooper, with a complementary product portfolio with attractive underlying growth, a scalable business model that can be rolled-out internationally, and strong online and digital marketing know-how.

Yvan Vindevogel, Chairman of Cooper, added: “We are thrilled to be bringing Bart on board. His wealth of experience in the sector will be central to helping us accelerate Cooper’s ambitious growth plans. I also want to thank Bauke for his dedication in building the company during an extraordinary period over the last 2 years. We are tremendously excited about the future and in particular about our new partnership with Lashilé Beauty, a partnership which will be highly complementary to both businesses, helping us provide our customers with more ways to look after their health and wellbeing.”

Bart Meermans, incoming CEO of Cooper, said: “I am delighted to join the Cooper team and I look forward to working with my new colleagues as we embark on the journey of becoming a leading European Healthcare company. I believe that providing self-care, by empowering people to take better care of their health, is meaningful and inspirational, and equally unlocking a significant runway for growth.”

On the acquisition of Cooper, CVC partnered with Vemedia founder Yvan Vindevogel, specialised healthcare fund Avista Capital Partners, the management team, and Charterhouse which made a significant reinvestment in the company. The Lashilé Beauty founders will also become shareholders in Cooper. The entry into exclusive negotiations was initially announced earlier this year and the new shareholders are excited to support the company’s organic and acquisitive growth plans.

ENDS

About Cooper Consumer Health

Cooper Consumer Health is a leading pan-European pure-play selfcare platform with net sales totalling € 500 million. The group has direct presence in 6 core European markets and addresses more than 30 export countries where it markets a wide portfolio of well-established brands such as Valdispert®, Oenobiol®, Mag2®, Etiaxil®, etc.. Cooper Consumer Health employs 850 people.

About CVC

CVC is a leading private equity and investment advisory firm with a network of 25 offices throughout Europe, Asia and the US, with approximately US$125 billion of assets under management. Since its founding in 1981, CVC has secured commitments in excess of US$165 billion from some of the world’s leading institutional investors across its private equity and credit strategies. Funds managed or advised by CVC are invested in more than 100 companies worldwide, which have combined annual sales of over US$100 billion and employ more than 450,000 people. For further information about CVC please visit: www.cvc.com.